Virginia Cancer Institute
Virginia Cancer Institute
 
 

At Virginia Cancer Institute, we provide treatment, support, and follow-up care for people with cancer and blood disorders. Our purpose is to provide our patients with care that includes efficiency and compassion. The Virginia Cancer Institute is committed to offering care in an atmosphere of professionalism, encouragement, and understanding. Virginia Cancer Institute serves you by offering the best treatment plans, answering questions to your satisfaction, and respecting your informed decisions.

Virginia Cancer Institute's mission is to deliver high-quality, comprehensive medical care while maintaining our patients' quality of life. We offer a team approach for your cancer treatment by involving experts in medical oncology, hematology, chemotherapy, and clinical research.

The goal of our Web site is to:

  • Provide information about our programs, special services, physicians, and other health care professionals.
  • Help you understand your diagnosis and treatment choices.
  • Keep you focused on your quality of life.

We strive to promote respect, understanding, honesty, compassion, integrity, teamwork, individuality, and confidentiality at all times. We will remain committed to our purpose by remaining innovative and continuously increasing our awareness of technological advancements and the latest treatment methods. The physicians and staff continue to strive to remain dedicated to this mission.

Virginia Cancer Institute is dedicated to understanding the causes, prevention, and detection of cancer and to improving the quality of life for individuals living with cancer. Virginia Cancer Institute strives to be in the forefront of modern cancer care through the thoughtful introduction of promising new methods of treatment, the active participation in clinical research, the recruitment, development and education of highly trained oncology personnel, and the use of state-of-the art medical equipment.

 
 
Latest Cancer News

PET/CT Improves Detection of Inoperable Lung Cancer (07/02/2009)
Preoperative lung cancer staging with combined PET/CT imaging allows some patients to avoid futile surgery. These results were published in the New England Journal of Medicine.

Amgen Helps Reduce Out-of-pocket Costs for Neulasta® (07/02/2009)
Amgen’s Neulasta FIRST STEP™ Program provides assistance to eligible, low-income, commercially-insured chemotherapy patients who need help with their co-insurance or co-payment requirement for Neulasta® (pegfilgrastim).

Sutent® Fails to Show Benefit in Metastatic Colorectal Cancer (07/01/2009)
The combination of the targeted therapy Sutent® (sunitinib) and FOLFIRI chemotherapy did not result in better progression-free survival than FOLFIRI alone among patients with metastatic colorectal cancer, prompting a Phase III clinical trial of the combination treatment to be stopped early. This information was made available in a press release from Pfizer.